Exact Sciences Corporation (NASDAQ:EXAS) went up by 6.84% from its latest closing price compared to the recent 1-year high of $141.90. The company’s stock price has collected 2.37% of gains in the last five trading sessions. Press Release reported on 12/11/20 that New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score(R) Test in Shaping Clinical Practice
Is It Worth Investing in Exact Sciences Corporation (NASDAQ :EXAS) Right Now?
Plus, the 36-month beta value for EXAS is at 1.65. Opinions of the stock are interesting as 12 analysts out of 15 who provided ratings for Exact Sciences Corporation declared the stock was a “buy,” while 1 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $150.43, which is $14.39 above the current price. Today, the average trading volume of EXAS was 2.15M shares.
EXAS’s Market Performance
EXAS stocks went up by 2.37% for the week, with a monthly jump of 17.64% and a quarterly performance of 75.60%, while its annual performance rate touched 50.10%. The volatility ratio for the week stands at 4.86% while the volatility levels for the past 30 days are set at 4.66% for Exact Sciences Corporation. The simple moving average for the period of the last 20 days is 9.16% for EXAS stocks with a simple moving average of 51.33% for the last 200 days.
Analysts’ Opinion of EXAS
Many brokerage firms have already submitted their reports for EXAS stocks, with UBS repeating the rating for EXAS by listing it as a “Neutral.” The predicted price for EXAS in the upcoming period, according to UBS is $140 based on the research report published on October 29th of the current year 2020.
Citigroup, on the other hand, stated in their research note that they expect to see EXAS reach a price target of $140, previously predicting the price at $120. The rating they have provided for EXAS stocks is “Neutral” according to the report published on October 28th, 2020.
BTIG Research gave a rating of “Buy” to EXAS, setting the target price at $140 in the report published on October 08th of the current year.
EXAS Trading at 14.40% from the 50-Day Moving Average
After a stumble in the market that brought EXAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.13% of loss for the given period.
Volatility was left at 4.66%, however, over the last 30 days, the volatility rate increased by 4.86%, as shares surge +21.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.46% upper at present.
During the last 5 trading sessions, EXAS rose by +2.37%, which changed the moving average for the period of 200-days by +94.18% in comparison to the 20-day moving average, which settled at $125.81. In addition, Exact Sciences Corporation saw 47.10% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at EXAS starting from Zanotti Katherine S, who sale 20,000 shares at the price of $132.06 back on Dec 14. After this action, Zanotti Katherine S now owns 21,907 shares of Exact Sciences Corporation, valued at $2,641,182 using the latest closing price.
Conroy Kevin T, the President and CEO of Exact Sciences Corporation, sale 30,577 shares at $124.56 during a trade that took place back on Dec 01, which means that Conroy Kevin T is holding 857,518 shares at $3,808,660 based on the most recent closing price.
Stock Fundamentals for EXAS
Current profitability levels for the company are sitting at:
- -19.51 for the present operating margin
- +73.44 for the gross margin
The net margin for Exact Sciences Corporation stands at -9.59. The total capital return value is set at -7.40, while invested capital returns managed to touch -3.64. Equity return is now at value -13.80, with -8.00 for asset returns.
Based on Exact Sciences Corporation (EXAS), the company’s capital structure generated 41.74 points at debt to equity in total, while total debt to capital is 29.45. Total debt to assets is 27.24, with long-term debt to equity ratio resting at 41.36. Finally, the long-term debt to capital ratio is 29.18.
When we switch over and look at the enterprise to sales, we see a ratio of 14.57, with the company’s debt to enterprise value settled at 0.07. The receivables turnover for the company is 9.84 and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.36.